CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 145 filers reported holding CATALYST PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 1.85 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $350,700 | -13.0% | 30,000 | 0.0% | 0.04% | -10.6% |
| Q2 2023 | $403,200 | -18.9% | 30,000 | 0.0% | 0.05% | -23.0% |
| Q1 2023 | $497,400 | -10.9% | 30,000 | 0.0% | 0.06% | -12.9% |
| Q4 2022 | $558,000 | +44.9% | 30,000 | 0.0% | 0.07% | +32.1% |
| Q3 2022 | $385,000 | +83.3% | 30,000 | 0.0% | 0.05% | +12.8% |
| Q2 2022 | $210,000 | -15.7% | 30,000 | 0.0% | 0.05% | +56.7% |
| Q1 2022 | $249,000 | -8.1% | 30,000 | -25.0% | 0.03% | -9.1% |
| Q4 2021 | $271,000 | +27.8% | 40,000 | 0.0% | 0.03% | +17.9% |
| Q3 2021 | $212,000 | -7.8% | 40,000 | 0.0% | 0.03% | -45.1% |
| Q2 2021 | $230,000 | +25.0% | 40,000 | 0.0% | 0.05% | +13.3% |
| Q1 2021 | $184,000 | +37.3% | 40,000 | 0.0% | 0.04% | +28.6% |
| Q4 2020 | $134,000 | +12.6% | 40,000 | 0.0% | 0.04% | -5.4% |
| Q3 2020 | $119,000 | -35.7% | 40,000 | 0.0% | 0.04% | -42.2% |
| Q2 2020 | $185,000 | – | 40,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 148,281 | $1,902,000 | 5.68% |
| GABLES CAPITAL MANAGEMENT INC. | 433,814 | $5,566,000 | 4.46% |
| Quantedge Capital Pte Ltd | 503,700 | $6,462,000 | 1.99% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,896,000 | $62,816,000 | 1.25% |
| Lanham O'Dell & Company, Inc. | 20,145 | $258,000 | 0.92% |
| Capital Impact Advisors, LLC | 59,301 | $907,000 | 0.90% |
| SummerHaven Investment Management, LLC | 98,840 | $1,268,000 | 0.88% |
| Yorktown Management & Research Co Inc | 50,000 | $642,000 | 0.83% |
| GLOBEFLEX CAPITAL L P | 304,293 | $3,904,000 | 0.67% |
| AFFINITY INVESTMENT ADVISORS, LLC | 90,864 | $1,166,000 | 0.60% |